HMN 2025: How Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer
Health Medicine Network,
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed…